AxoGen

AxoGen R&D per Employee

The R&D Spending per Employee of AxoGen (AXGN) as of Sep 22, 2026 is 52,869.77 USD. In the previous year, R&D Spending per Employee was 44,641.48 USD — a change of 18.43% (higher).

R&D per Employee

52,869.77USD

YoY

18.43%

Last updated:

R&D Spending per Employee of AxoGen is 2026 52,869.77 USD. R&D Spending per Employee of AxoGen was 2025 44,641.48 USD. It decreases by 18.43% higher compared to the previous year.

The AxoGen R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
18,927.65 USD
Jan 1, 2019
28,157.56 USD
Jan 1, 2020
28,691.32 USD
Jan 1, 2021
38,869.77 USD
Jan 1, 2022
41,200.96 USD
Jan 1, 2023
43,953.38 USD
Jan 1, 2024
44,641.48 USD
Jan 1, 2025
52,869.77 USD
The AxoGen R&D per Employee history
YEARR&D per EmployeeYoY
52,869.77USD+18.43%
44,641.48USD+1.57%
43,953.38USD+6.68%
41,200.96USD+6.00%
38,869.77USD+35.48%
28,691.32USD+1.90%
28,157.56USD+48.76%
18,927.65USD+75.74%
10,770.29USD+59.05%
6,771.74USD+30.11%
5,204.45USD+6.72%
4,876.73USD
Access this data via the Eulerpool API

AxoGen Stock analysis

What does AxoGen do? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AxoGen stock

R&D Spending per Employee of AxoGen is 52,869.77 USD in 2026.

R&D Spending per Employee of AxoGen changed from 44,641.48 USD to 52,869.77 USD, representing a 18.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee AxoGen since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's AxoGen historically and in real time.

Access this data via the Eulerpool API

Workforce — AxoGen

All Key Metrics — AxoGen